insideALS for HCPs is…

a place where healthcare professionals who are interested in learning more about the rapidly changing science of genetic ALS can find content co-created with medical experts in the field.

“I believe genetic testing across all ALS patients is critical to find those who have genetic ALS.”

Dr. Caroline Ingre, MD, PhD

Karolinska University Hospital, Stockholm, Sweden

These healthcare professionals are paid consultants for Biogen.

“There will be an explosion in information needs for people with ALS and their families, and thereby healthcare professionals and those supporting them.”

Dr. Christopher McDermott

Sheffield Institute for Translational Neuroscience, Sheffield, England

These healthcare professionals are paid consultants for Biogen.

“Focusing on genetics and being disciplined and collaborative is the way we move forward in ALS care.”

Prof. Orla Hardiman

Trinity College Dublin, Dublin, Ireland

These healthcare professionals are paid consultants for Biogen.

“Genetic markers are a valuable way to differentiate what ALS could look like on an individual level.”

Dr. Caroline Ingre, MD, PhD

Karolinska University Hospital, Stockholm, Sweden

These healthcare professionals are paid consultants for Biogen.

“We have always hoped that genetics would allow us to better understand ALS. Now we know it is possible.”

Prof. Philippe Corcia

Centre SLA, CHU Bretonneau in Tours, France

These healthcare professionals are paid consultants for Biogen.

“Learning more about the relation between genetics and ALS is an avenue to better understanding ALS.”

Prof. Albert Ludolph

Academic Neuroscience Centre of the University of Ulm, Ulm, Germany

These healthcare professionals are paid consultants for Biogen.

“I think it's important to acknowledge that science is, in every sense, moving forward and we should embrace that and use that.”

Dr. Caroline Ingre, MD, PhD

Karolinska University Hospital, Stockholm, Sweden

These healthcare professionals are paid consultants for Biogen.

“Research continues to expand our vision of ALS, quickly increasing what we can learn from genetics in ALS.”

Prof. Leonard van den Berg

UMC Utrecht, Utrecht, Netherlands

These healthcare professionals are paid consultants for Biogen.

“Now we may be able to identify genetic mutations associated with the disease, and, not only that, we can perhaps enroll patients into a clinical trial.”

Dr. Lorne Zinman

Sunnybrook Research Institute, Toronto, Ontario

These healthcare professionals are paid consultants for Biogen.

Sponsored by Biogen and offered through Invitae

No-charge genetic testing for patients living with ALS and their families

Biogen-sponsored genetic testing offered through Invitae includes more than 20 ALS-associated genes.

Find out more

About ALS

Genetic ALS

Healthcare professional working with high technology tools

Developments in genetic ALS research

Genetic testing

Healthcare professional reassuring patient

Supporting patients living with ALS

Do your patients have questions about genetic ALS? This PDF of important facts could help.

Download the Genetic ALS Fast Facts PDF to share with your patients.

Download PDF

References: 1. Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. NEJM. 2017; 377: 162-72. 2. Nguyen HP, Van Broeckhoven C, van der Zee J. ALS Genes in the Genomic Era and their Implications for FTD. Trends Genet. 2018;34(6):404-423. 3. Roggenbuck J, Quick A, Kolb SJ. Genetic testing and genetic counselling for amyotrophic lateral sclerosis: an update for clinicians. Genet Med. 2017;19(3):267-274. 4. Boylan K. Familial amyotrophic lateral sclerosis. Neurol Clin. 2015;33(4):807-830. 5. Shepheard SR, Parker MD, Cooper-Knock J, et al; on behalf of Project MINE Consortium; Project MinE. Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2021;92(5):510-518. 6. Benatar M, Stanislaw C, Reyes E, et al. Presymptomatic ALS genetic counseling and testing: experience and recommendations. Neurology. 2016;86(24):2295-2302. 7. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942-955.

References

1. Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. NEJM. 2017; 377: 162-72. 2. Nguyen HP, Van Broeckhoven C, van der Zee J. ALS Genes in the Genomic Era and their Implications for FTD. Trends Genet. 2018;34(6):404-423. 3. Roggenbuck J, Quick A, Kolb SJ. Genetic testing and genetic counselling for amyotrophic lateral sclerosis: an update for clinicians. Genet Med. 2017;19(3):267-274. 4. Boylan K. Familial amyotrophic lateral sclerosis. Neurol Clin. 2015;33(4):807-830. 5. Shepheard SR, Parker MD, Cooper-Knock J, et al; on behalf of Project MINE Consortium; Project MinE. Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2021;92(5):510-518. 6. Benatar M, Stanislaw C, Reyes E, et al. Presymptomatic ALS genetic counseling and testing: experience and recommendations. Neurology. 2016;86(24):2295-2302. 7. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942-955.